Linerixibat

Linerixibat
Clinical data
Trade namesLynavoy
Other namesGSK-2330672
AHFS/Drugs.comMonograph
MedlinePlusa626054
License data
Routes of
administration		By mouth
Drug classIleal bile acid transporter inhibitor
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC28H38N2O7S
Molar mass546.68 g·mol−1
3D model (JSmol)
  • CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC
  • InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
  • Key:CZGVOBIGEBDYTP-VSGBNLITSA-N

Linerixibat, sold under the brand name Lynavoy, is a medication used for the treatment of cholestatic pruritus. Linerixibat is an ileal bile acid transporter (IBAT) inhibitor.[1][2] It is taken by mouth.[1]

Linerixibat was approved for medical use in the United States in March 2026.[3][4][5]

Medical uses

Linerixibat is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis in adults.[1]

Society and culture

Linerixibat was approved for medical use in the United States in March 2026.[4]

Names

Linerixibat is the international nonproprietary name.[6]

Linerixibat is sold under the brand name Lynavoy.[7]

References

  1. 1 2 3 4 "Lynavoy- linerixibat tablet, film coated". DailyMed. 11 June 2026. Retrieved 26 July 2026.
  2. ↑ Silveira IB, Rezende RA, Neto CA, Rossi YI, Leite MD, Cançado GG (August 2025). "Ileal Bile Acid Transporter Inhibitors for Adult Patients with Autoimmune Cholestatic Liver Diseases: A Systematic Review and Meta-Analysis". Gastroenterology Insights. 16 (3): 30. doi:10.3390/gastroent16030030.
  3. ↑ "Drug Approval Package: Lynavoy". U.S. Food and Drug Administration (FDA). 13 May 2026. Retrieved 26 July 2026.
  4. 1 2 "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 26 March 2026. Retrieved 5 April 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ↑ "Lynavoy (linerixibat) FDA Approval History". Drugs.com. 20 March 2026. Retrieved 24 March 2026.
  6. ↑ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
  7. ↑ "Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)". GSK (Press release). 19 March 2026. Retrieved 5 April 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.